KRAS and cancer: Our data confirm that PKM2 and its direct substrate, c-Myc, are major players of KRAS mutation-induced cancer by performing various metabolic (i.e., positive effect on GLUT1) and non-metabolic (i.e., up-regulation of autophagy) functions.